These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22687642)

  • 41. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
    Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
    Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
    Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
    Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
    Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
    Yamanouchi T; Sakai T; Igarashi K; Ichiyanagi K; Watanabe H; Kawasaki T
    Diabet Med; 2005 Aug; 22(8):980-5. PubMed ID: 16026361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.
    Dorkhan M; Magnusson M; Frid A; Grubb A; Groop L; Jovinge S
    J Intern Med; 2006 Aug; 260(2):125-33. PubMed ID: 16882276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
    Sharma SK; Verma SH
    J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
    Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes.
    Kong AP; Yamasaki A; Ozaki R; Saito H; Asami T; Ohwada S; Ko GT; Wong CK; Leung GT; Lee KF; Yeung CY; Chan JC
    Diabetes Obes Metab; 2011 Sep; 13(9):806-13. PubMed ID: 21492364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
    Van Raalte DH; van Genugten RE; Eliasson B; Möller-Goede DL; Mari A; Tura A; Wilson C; Fleck P; Taskinen MR; Smith U; Diamant M
    Eur J Endocrinol; 2014 Apr; 170(4):565-74. PubMed ID: 24421302
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production.
    Ye Y; Lin Y; Perez-Polo JR; Uretsky BF; Ye Z; Tieu BC; Birnbaum Y
    J Immunol; 2008 Sep; 181(5):3515-23. PubMed ID: 18714024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.